Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

COMMENTED

Migraine and Headache

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab

Cephalalgia.

Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA

doi: 10.1177/0333102418789072.

Migraine and Headache

Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients

Neurol Sci.

Fekrazad R, Sardarian A, Azma K, Karami M, Borhani-Haghighi A, Gharesi-Fard B, Movahedi B

doi: 10.1007/s10072-018-3340-3.

RECOMMENDED

Migraine and Headache

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

doi: 10.1177/0333102419835459.

Migraine and Headache

Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class

Headache.

Hargreaves R, Olesen J

doi: 10.1111/head.13510.

Migraine and Headache

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies

Headache.

Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, Aurora SK

doi: 10.1111/head.13691.

Migraine and Headache

Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial

JAMA Neurol.

Vollesen ALH, Snoer A, Beske RP, Guo S, Hoffmann J, Jensen RH, Ashina M

doi: 10.1001/jamaneurol.

RECOMMENDED

Migraine and Headache

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine

N Engl J Med.

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ

doi: 10.1056/NEJMoa1811090.

Migraine and Headache

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

Headache

Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD

doi: 10.1111/head.14138

Migraine and Headache

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study

Headache

Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC

doi: 10.1111/head.14196

Related content

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab

Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies

Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study